KBI Biopharma teams up with AbSci to promote each other’s technologies
RESEARCH TRIANGLE PARK, N.C. — KBI Biopharma, a biopharmaceutical cAbSci, the Protein Printing™ company with a best-in-class E. coli cell line for rapid and low-cost biomanufacturing of complex biotherapeutics, today announced the completion of a $10.4M Series D financing led by KBI Biopharma and JSR Life Sciencesract services organization with offices in Durham and RTP, has entered into an exclusive co-marketing agreement with the Washington-based biopharma tech company, AbSci. The uptick: both get the privilege to jointly market and promote each other’s...
Read More410 Medical’s LifeFlow device wins healthcare fans, major contract
RALEIGH — A hand-held fluid resuscitation device developed by Durham start-up 410 Medical has been generating major buzz and billings for its unique design and pot LifeFlow is a hand-operated infuser that combines a syringe, automatic check valve and high-flow tubing set. It was designed by physician Mark Piehl at WakeMed Health & Hospitals in Raleigh to help a single caregiver inject resuscitating fluids quickly and easily with less stress in emergency situations. The company says LifeFlow lowers risk of organ failure due to its ability to deliver fluids more efficiently. ential...
Read MoreMedical device firm Contego Medical lands $22.3M from investors
RALEIGH, N.C. – Contego Medical, a Raleigh-based medical device firm that received FDA approval for two systems targeting neurovascular, coronary and peripheral vascular disease, has landed $22 million from 10 investors. Contego disclosed the funding in an SEC filing. In 2018, Conteo Medical received FDA approval for: The Vanguard IEP Peripheral Balloon Angioplasty System with Integrated Embolic Protection.The “first” filter-based Integrated Embolic Protection (IEP) device, the Paladin Carotid PTA Balloon System. Contego CEO Ravish Sachar signed the filing. The...
Read MoreWith $65M in funding, UNC spinout Pinnacle Hill backs professor’s blood cancer research
CHAPEL HILL, N.C. – Researchers at the University of North Carolina at Chapel Hill are one step closer to a possible new treatment against multiple myeloma, a devastating type of blood cancer. That’s because their project now has the backing of Pinnacle Hill, the drug spinout company formed in partnership with UNC and Deerfield Management, a New York-based health care investment firm. The firm recently said it would support a project led by Lindsey Ingerman James, Ph.D., a UNC Eshelman School of Pharmacy chemical biology and medicinal chemistry division...
Read MoreLocus Biosciences to launch major gene editing trial
MORRISVILLE, N.C. – Locus Biosciences, a developer of precision antibacterial therapies, will conduct the world’s first clinical trial of a recombinant bacteriophage therapy, a major milestone for the field, the company announced. Locus has opened enrollment for a Phase 1b trial of a potential treatment for urinary tract infections caused by Escherichia coli (E. coli) bacteria. The study will evaluate LBP-EC01, a bacteriophage “cocktail” that has been engineered with the gene editing technology CRISPR Cas3 to target the E. coli genome. “This trial represents a major...
Read MoreAegle Therapeutics Announces $4M Financing to Fund Groundbreaking Stem Cell Exosome Clinical Trial to Treat Orphan Disease Dystrophic Epidermolysis Bullosa
BOSTON, MA. and MIAMI, FL. – Aegle Therapeutics Corp., a first in class biotechnology company isolating extracellular vesicles, including exosomes (“EVs”), secreted by mesenchymal stem cells as therapy, today announced the closing of a $4M financing. Aegle’s platform technology is initially being developed to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric skin blistering disorder. The investment was led by Boca Raton-based New World Angels, with participation from Tellus BioVentures, DEFTA Healthcare Technologies and DeepWork...
Read More
Follow Us!